Pediatric Rheumatology

, 6:P44 | Cite as

Efficacy of a second TNF blocker, when the first one failed, in patients with juvenile idiopathic arthritis (JIA)

  • A Salmaso
  • A Lurati
  • I Pontikaki
  • V Gerloni
  • M Gattinara
  • B Teruzzi
  • F Fantini
Open Access
Poster presentation
  • 1.2k Downloads

Keywords

Arthritis Infliximab Etanercept Juvenile Idiopathic Arthritis Psoriatic Arthritis 

Objectives

To determine the efficacy of a second treatment with a different TNF blocker in JIA when the first one failed.

Methods

All JIA patients prospectively followed at our Centre, who failed a first TNF blocker and switched to a second one were enrolled. For each patient the DAS, ACR Ped30, ACR20, ACR50 and ACR70 responses were evaluated at baseline and after a period ranging from 3 to 6 months of each treatment.

Results

Out of 60 JIA patients enrolled, 40 (37 f, 3 m) were evaluated: 10 systemic arthritis, 2 persistent oligoarthritis, 11 extended oligoarthritis, 9 RF negative polyarthritis, 4 RF positive polyarthritis, 1 ERA (enthesitis related arthritis), 3 psoriatic arthritis. With a standard Chi square model, we didn't find a significant difference in the ACR and DAS response rates between the first and the second anti TNF treatment (p > 0.1). Stratifying the population for the type of the shift (Etanercept to Infliximab/Adalimumab, Infliximab to Etanercept/Adalimumab) we didn't find a significant difference in the ACR and DAS response rates between the first and the second anti TNF treatment (p > 0.1). Our data show that failure of an anti-TNF therapy in patients with JIA does not preclude a response to a second anti-TNF agent of a different class.

Copyright information

© Salmaso et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Authors and Affiliations

  • A Salmaso
    • 1
  • A Lurati
    • 2
  • I Pontikaki
    • 1
  • V Gerloni
    • 1
  • M Gattinara
    • 1
  • B Teruzzi
    • 1
  • F Fantini
    • 1
  1. 1.Gaetano Pini Institute Chair of RheumatologyMilanItaly
  2. 2.Fornaroli Hospital Rheumatology UnitMagentaItaly

Personalised recommendations